NCT03851939Unknown2 期
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC): A Prospective, Single-armed, Stage II Clinical Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2019年2月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
To evaluate the efficacy of TAI combine toripalimab in advanced HCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •older than 18 years old and younger than 75 years;
- •ECOG PS≤1;
- •proven advanced hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria;
- •not previous treated for tumor;
- •cannot accepted hepatectomy;
- •the lab test could meet:
- •neutrophil count≥2.0×109/L;
- •hemoglobin≥100g/L;
- •platelet count≥75×109/L;
- •serum albumin≥35g/L;
- •total bilirubin<2-times upper limit of normal;
- •ALT<3-times upper limit of normal;
- •AST<3-times upper limit of normal;
- •serum creatine<1.5-times upper limit of normal;
- •PT≤upper limit of normal plus 4 seconds;
- •sign up consent;
排除标准
- •cannot tolerate TAI or toripalimab;
- •known history of other malignancy;
- •be allergic to related drugs;
- •underwent organ transplantation before;
- •be treated before (interferon included);
- •known history of HIV infection;
- •known history of drug or alcohol abuse;
- •have GI hemorrhage or cardiac/brain vascular events within 30 days;
- •pregnancy;
结局指标
主要结局
PFS
时间窗: From date of randomization until the date of progression, assessed up to 36 months
progression-free survival
ORR
时间窗: From date of randomization until the date of death, assessed up to 36 months
objective response rate
次要结局
- DCR(From date of randomization until the date of death, assessed up to 36 months)
- OS(From date of randomization until the date of death from any cause, assessed up to 36 months)
研究者
Rong-ping Guo
Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT03851887Sun Yat-sen University33
Unknown
3 期
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT04053985Sun Yat-sen University206
已完成
2 期
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT06232759Guangxi Medical University56
招募中
不适用
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTTHepatocellular Carcinoma Non-resectableNCT04967495Second Affiliated Hospital of Guangzhou Medical University171
Unknown
2 期
TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCTransarterial ChemoembolizationHepatocellular CarcinomaNCT04597970Peking University Cancer Hospital & Institute66